A BILL 
To require the Federal Trade Commission to study the role 
of intermediaries in the pharmaceutical supply chain and 
provide Congress with appropriate policy recommenda-
tions, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Prescription Pricing 
4
for the People Act of 2019’’. 
5
01:29 Apr 30, 2019
H2376
2 
•HR 2376 IH
SEC. 2. DEFINITIONS. 
1
In this Act: 
2
(1) 
APPROPRIATE
COMMITTEES
OF
CON-
3
GRESS.—The term ‘‘appropriate committees of Con-
4
gress’’ means— 
5
(A) the Committee on the Judiciary of the 
6
Senate; and 
7
(B) the Committee on the Judiciary of the 
8
House of Representatives. 
9
(2) COMMISSION.—The term ‘‘Commission’’ 
10
means the Federal Trade Commission. 
11
SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN 
12
INTERMEDIARIES AND MERGER ACTIVITY. 
13
(a) INITIAL REPORT.—Not later than 1 year after 
14
the date of enactment of this Act, the Commission shall 
15
submit to the appropriate committees of Congress a report 
16
that— 
17
(1) addresses at minimum— 
18
(A) whether pharmacy benefit managers— 
19
(i) charge payers a higher price than 
20
the reimbursement rate at which the phar-
21
macy benefit managers reimburse com-
22
peting pharmacies; 
23
(ii) steer patients for anticompetitive 
24
purposes to any pharmacies, including re-
25
tail, mail-order, or any other type of phar-
26
01:29 Apr 30, 2019
H2376
3 
•HR 2376 IH
macy, in which the PBM has an ownership 
1
interest; 
2
(iii) audit or review proprietary data, 
3
including acquisition costs, patient infor-
4
mation, or dispensing information, of com-
5
peting pharmacies that can be used for 
6
anticompetitive purposes; or 
7
(iv) use formulary designs to increase 
8
the market share of higher cost prescrip-
9
tion drugs and depress the market share of 
10
lower cost prescription drugs (each net of 
11
rebates and discounts); 
12
(B) whether there are any specific legal or 
13
regulatory obstacles the Commission currently 
14
faces in ensuring a competitive and transparent 
15
marketplace in the pharmaceutical supply 
16
chain, including the pharmacy benefit manager 
17
marketplace and pharmacy services administra-
18
tive organizations; 
19
(C) how companies and payers assess the 
20
benefits, costs, and risks of contracting with 
21
intermediaries, including pharmacy services ad-
22
ministrative organizations, and whether more 
23
information about the roles of intermediaries 
24
01:29 Apr 30, 2019
H2376
4 
•HR 2376 IH
should be available to consumers and payers; 
1
and 
2
(D) whether there are any specific legal or 
3
regulatory obstacles the Commission currently 
4
faces in ensuring a competitive and transparent 
5
marketplace in the pharmaceutical supply 
6
chain, including the pharmacy benefit manager 
7
marketplace and pharmacy services administra-
8
tive organizations; and 
9
(2) provides— 
10
(A) observations or conclusions drawn 
11
from the November 2017 roundtable entitled 
12
‘‘Understanding Competition in Prescription 
13
Drug Markets: Entry and Supply Chain Dy-
14
namics’’, and any similar efforts; 
15
(B) specific actions the Commission in-
16
tends to take as a result of the November 2017 
17
roundtable, and any similar efforts, including a 
18
detailed description of relevant forthcoming ac-
19
tions, additional research or roundtable discus-
20
sions, consumer education efforts, or enforce-
21
ment actions; and 
22
(C) policy or legislative recommendations 
23
to— 
24
01:29 Apr 30, 2019
H2376
5 
•HR 2376 IH
(i) improve transparency and competi-
1
tion in the pharmaceutical supply chain; 
2
(ii) prevent and deter anticompetitive 
3
behavior in the pharmaceutical supply 
4
chain; and 
5
(iii) best ensure that consumers ben-
6
efit from any cost savings or efficiencies 
7
that may result from mergers and consoli-
8
dations. 
9
(b) INTERIM REPORT.—Not later than 180 days 
10
after the date of enactment of this Act, the Commission 
11
shall submit to the appropriate committees of Congress 
12
an interim report on the progress of the report required 
13
by subsection (a), along with preliminary findings and 
14
conclusions based on information collected to that date. 
15
Æ 
01:29 Apr 30, 2019
H2376
